Hyperoxaluria - Pipeline Insight, 2018 - ResearchAndMarkets.com

November 30, 2018

DUBLIN--(BUSINESS WIRE)--Nov 30, 2018--The “Hyperoxaluria - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Hyperoxaluria development.The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

ClinicalNon-clinicalInactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Hyperoxaluria pipeline products by developmental stage, product type, molecule type, and administration route.


The report provides a snapshot of the pipeline development for HyperoxaluriaThe report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for HyperoxaluriaThe report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical informationProvides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for HyperoxaluriaThe report also covers the dormant and discontinued pipeline projects related to Hyperoxaluria

Reasons to Purchase

Establish comprehensive understanding of the pipeline activity across this Hyperoxaluria to formulate effective R&D strategiesGather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantageIdentify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicinePlot corrective measures for pipeline projects by understanding the pipeline depth and focus of Hyperoxaluria therapeuticsDevise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeModify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Key Topics Covered

1. Report Introduction

2. Hyperoxaluria Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Hyperoxaluria

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name : Company Name

Product DescriptionResearch and DevelopmentProduct Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name : Company Name

Product DescriptionResearch and DevelopmentProduct Development Activities

7. Therapeutic Assessment

Assessment by Route of AdministrationAssessment by Stage and Route of AdministrationAssessment by Molecule TypeAssessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name : Company Name

Product DescriptionResearch and DevelopmentProduct Development Activities

Companies Featured

Allena PharmaceuticalsAlnylam PharmaceuticalsDicerna PharmaceuticalsDigna BiotechOxThera AB

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/3fj5gh/hyperoxaluria?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005437/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Liver and Kidney Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/30/2018 01:26 PM/DISC: 11/30/2018 01:26 PM


Update hourly